[1] |
SUN Qiyue, ZHAO Ronghua, BAO Lei, GUO Shanshan, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing.
Safe doses of Lingyang Ganmao oral liquid for children based on the multi-animal model
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 121-126.
|
[2] |
FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong.
Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
|
[3] |
LI Yingfen, HAN Lei.
Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
|
[4] |
LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue.
Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
|
[5] |
TAI Jun, YU Miao, ZHANG Lin, LEI Yi, LIU Junting, LI Tao, HUANG Guimin, CHENG Yijing, NIE Xiaolu, WANG Qing.
Active monitoring of adverse reactions related to haemocoagulase agkistrodon for injection in children
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1011-1016.
|
[6] |
SHI Xiangfen, SUN Zhiyong, ZHANG Xufeng, LU Xiaojing, DU Shuzhang, ZHANG Xiaojian.
Whole process management of narcotic drugs and psychotropic drugs based on intelligent information management system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 899-903.
|
[7] |
HUO Yanfei, TIAN Yuejie, XU Lili, XIE Yanjun, CHANG Hong, SUN Chunxiao, LI Xia.
535 reports of new and serious adverse drug reactions caused by preparations of lappaconitine hydrobromide
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 921-926.
|
[8] |
.
Annual report of national adverse drug reaction monitoring (2022)
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 712-719.
|
[9] |
FAN Xiucong, DONG Xiaohui, CHEN Danxia, BAO Siwei, MA Yabin.
Pharmaceutical care of a patient with Clostridium difficile infection and urinary tract infection during pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 579-582.
|
[10] |
ZHANG Zhiqi, GUO Mingxing, XU Ye, ZHANG Jian, LIN Jun, CUI Xiangli.
One case of tacrolimus-caused reversible posterior leukoencephalopathy syndrome after renal transplantation in children
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 465-468.
|
[11] |
JIA Zhaoguang, XU Wenshuai, JI Li’na, WANG Linlin, ZHAO Li’na, ZHAO Jingquan, MU Xiangdong.
Diagnosis and treatment of mycoplasma pneumoniae pneumonia in children and rational administration of related drugs
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1391-1395.
|
[12] |
PENG Jing, TUO Yali, LI Qiaoling, ZHOU Rong, LI Xinlin, PENG Hui.
Data analysis of adverse events of clobazam among children based on foreign pharmacovigilance safety spontaneous reporting system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1264-1268.
|
[13] |
CAO Xiaoyu, WANG Ying, WANG Jingwen, YANG Ruixia, GE Jie.
Analysis of agranulocytosis in a child induced by vancomycin injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 106-109.
|
[14] |
ZHANG Jingyu, ZHANG Yuanyuan, WANG Jing, MA Bo, LI Wenjuan.
Influencing factors of severe anaphylactic reactions of Yanhuning injections in children
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 1019-1022.
|
[15] |
XUN Xiaoqing, PENG Lingling.
Effects of sodium valproate on children with epilepsy and determinants of blood concentrations
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 1027-1029.
|